Similar articles

• Targeted re-sequencing of TET2 in Taiwanese patients with myelodysplastic/myeloproliferative neoplasms.

  Lin HC, Hwang DY, Lim KH. Lin HC, et al. Med Oncol. 2016 Aug;33(8):92. doi: 10.1007/s12032-016-0808-y. Epub 2016 Jul 14. Med Oncol. 2016. PMID: 27418193 No abstract available.
• Mutation in TET2 in myeloid cancers.

  Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Massé A, Kosmider O, Le Couedic JP, Robert F, Alberdi A, Lécluse Y, Plo I, Dreyfus FJ, Marzac C, Casadevall N, Lacombe C, Romana SP, Dessen P, Soulier J, Viguié F, Fontenay M, Vainchenker W, Bernard OA. Delhommeau F, et al. N Engl J Med. 2009 May 28;360(22):2289-301. doi: 10.1056/NEJMoa0810069. N Engl J Med. 2009. PMID: 19474426
• Evaluation of TET2 deletions in myeloid disorders: a fluorescence in situ hybridization analysis of 109 cases.

  Klaus M, Psaraki A, Mastrodemou S, Pyrovolaki K, Mavroudi I, Kalpadakis C, Papadaki HA. Klaus M, et al. Leuk Res. 2011 Mar;35(3):413-5. doi: 10.1016/j.leukres.2010.10.023. Epub 2010 Nov 18. Leuk Res. 2011. PMID: 21087791
• Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases.

  Gelsi-Boyer V, Brecqueville M, Devillier R, Murati A, Mozziconacci MJ, Birnbaum D. Gelsi-Boyer V, et al. J Hematol Oncol. 2012 Mar 21;5:12. doi: 10.1186/1756-8722-5-12. J Hematol Oncol. 2012. PMID: 22436456 Free PMC article. Review.
• Mutations in chronic myelomonocytic leukemia and their prognostic relevance.

  Jian J, Qiao Y, Li Y, Guo Y, Ma H, Liu B. Jian J, et al. Clin Transl Oncol. 2021 Sep;23(9):1731-1742. doi: 10.1007/s12094-021-02585-x. Epub 2021 Apr 16. Clin Transl Oncol. 2021. PMID: 33861431 Review.